Patency and morphology of fibrous polyurethane vascular prostheses implanted in the femoral artery of dogs after seeding with subcultivated endothelial cells.
A cell culture line was established from enzymatically-derived canine jugular endothelial cells and further cultured. Whenever sufficient cells were present, fibrous polyurethane vascular prostheses, impregnated with gelatin and coated with fibronectin, were seeded with 4.8 x 10(5)/cm2 cells, sufficient to establish a confluent monolayer, and implanted in the femoral arteries of 16 dogs. A non-seeded prosthesis on the contralateral side served as control. Eight dogs received antiplatelet aggregation medication: 250 mg aspirin together with 25 mg dipyridamole, orally three times daily, starting 2 weeks prior to the implantation operation and continued for the duration of the experiment. Results show that in the non-medicated dogs all control prostheses become occluded within 3 weeks after implantation, whereas five out of eight seeded prostheses remained patent. In the medicated group, two out of eight control prostheses occluded and all seeded prostheses remained patent. Scanning and light microscopy revealed that seeded prostheses were completely lined with endothelial cells (Factor VIII positive stain) week 3 (n = 3) and 12 (n = 3) after implantation, while endothelialisation in control prostheses had advanced only 5 mm into the prostheses in 12 weeks. Two dogs of each group were included in long-term patency studies. We conclude that prostheses seeded with a confluent monolayer of endothelial cells result in superior patency rates for both medicated and non-medicated dogs. No immunological reaction against the (allogeneic) seeded endothelial cells were noted.
Hess
F
F
Laboratory of Cell biology and Histology, University of Nijmegen, The Netherlands.
Steeghs
S
S
Jerusalem
R
R
Reijnders
O
O
Jerusalem
C
C
Braun
B
B
Grande
P
P
D000714:Anastomosis, Surgical; D000818:Animals; D001241:Aspirin / Q000008:administration & dosage; D001807:Blood Vessel Prosthesis; D002478:Cells, Cultured / Q000473:pathology / Q000637:transplantation; D004176:Dipyridamole / Q000008:administration & dosage; D004285:Dogs; D004334:Drug Administration Schedule; D004730:Endothelium, Vascular / Q000473:pathology / Q000637:transplantation*; D005263:Femoral Artery / Q000473:pathology / Q000601:surgery; D005353:Fibronectins; D006083:Graft Occlusion, Vascular / Q000473:pathology*; D008855:Microscopy, Electron, Scanning; D011140:Polyurethanes; D011474:Prosthesis Design; D013499:Surface Properties
D005353:Fibronectins; D011140:Polyurethanes; D004176:Dipyridamole; D001241:Aspirin